Atopobium vaginae

^[1]^[2]^[3]

Pathology

etiologic agent of bacterial vaginosis^[1]
- may be associated with 80% of cases^[1], especially with therapeutic failures

variably resistant to metronidazole
resistant to nalidixic acid, colistin
nifuratel is not approved for use in the United States
clindamycin effective but also affects lactobacilli, altering the vaginal environment^[1]
susceptible to azithromycin, penicillin, ciprofloxacin^[3]

↑ ^1.0 ^1.1 ^1.2 ^1.3 Polatti F Bacterial Vaginosis, Atopobium vaginae and Nifuratel. Curr Clin Pharmacol. 2012 Feb; 7(1): 36-30 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22082330 Free PMC Article
↑ Ferris MJ Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis. 2004 Feb 13;4:5. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/15018635 Free PMC Article <Internet> http://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-4-5
↑ ^3.0 ^3.1 De Backer E, Verhelst R, Verstraelen H et al Antibiotic susceptibility of Atopobium vaginae. BMC Infect Dis. 2006 Mar 16;6:51 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/16542416 Free PMC Article <Internet> http://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-6-51